| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/CLINIDS/18.4.501 |
| P698 | PubMed publication ID | 8038304 |
| P2093 | author name string | T J Marrie | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 501-13; quiz 514-5 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Community-acquired pneumonia | |
| P478 | volume | 18 |
| Q35555252 | A cluster-randomized controlled trial of a multicomponent intervention protocol for pneumonia prevention among nursing home elders |
| Q43841508 | A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial |
| Q33757861 | A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae |
| Q37884013 | A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission |
| Q33676506 | A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis |
| Q35138007 | Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. |
| Q35770528 | Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care? |
| Q33604922 | Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital |
| Q81141936 | Agreement between emergency physician diagnosis and radiologist reports in patients discharged from an emergency department with community-acquired pneumonia |
| Q43573851 | Appropriate use of antibiotics in hospitals. Investigating clinical practices in management of community-acquired pneumonia |
| Q40986224 | Appropriateness of hospitalization of patients with community-acquired pneumonia |
| Q71103611 | Are outbreaks and sporadic respiratory infections by Mycoplasma pneumoniae due to two distinct subtypes? |
| Q41769578 | Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures? |
| Q33691963 | Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group |
| Q33573302 | Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections |
| Q37138461 | Chest radiography for predicting the cause of febrile illness among inpatients in Moshi, Tanzania |
| Q34017133 | Clarithromycin in the management of community-acquired pneumonia |
| Q64133444 | Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia |
| Q28344357 | Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group |
| Q88185101 | Clinical mimics: an emergency medicine focused review of pneumonia mimics |
| Q73235113 | Community-Acquired Pneumonia: An Overview |
| Q77464123 | Community-acquired pneumonia |
| Q35148142 | Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management |
| Q73662742 | Community-acquired pneumonia: reality revisited |
| Q80397858 | Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae |
| Q35137307 | Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia |
| Q34223608 | Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection |
| Q27024997 | Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke |
| Q37877605 | De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. |
| Q37864671 | Development of a hamster model of Chlamydophila pneumoniae infection. |
| Q34127404 | Diagnosis of pneumonia and monitoring of infection eradication |
| Q38729676 | Disease burden of community acquired pneumonia among children under 5 y old in China: A population based survey |
| Q71347422 | Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia |
| Q34404666 | Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment |
| Q57991308 | Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin |
| Q35110637 | Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis |
| Q34756483 | Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children |
| Q35957889 | Epidemiology and etiology of community-acquired pneumonia |
| Q26823787 | Epidemiology of community-acquired pneumonia in children of Latin America and the Caribbean: a systematic review and meta-analysis |
| Q37867617 | Experimental infection by Chlamydia pneumoniae in the hamster |
| Q38428196 | Factors associated with hospitalization costs for patients with community acquired pneumonia |
| Q33571822 | Formulary management of macrolide antibiotics |
| Q34419979 | Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia |
| Q54245877 | Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis. |
| Q74273337 | Intra and inter technologist variability in the quality assessment of respiratory tract specimens |
| Q37878512 | Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia |
| Q35892967 | Laboratory diagnosis of Chlamydia pneumoniae infections |
| Q36530445 | Lung epithelium as a sentinel and effector system in pneumonia--molecular mechanisms of pathogen recognition and signal transduction |
| Q25257188 | Measurement of complement receptor 1 on neutrophils in bacterial and viral pneumonia |
| Q33749721 | Nonresolving or slowly resolving pneumonia |
| Q73261808 | Ongoing issues in pneumonia care: when to admit, how to treat and the role of oral therapy |
| Q35124715 | Paediatric community-acquired pneumonia: current concept in pharmacological control |
| Q30406799 | Pneumococcal disease manifestation in children before and after vaccination: what's new? |
| Q78001602 | Pneumonia as a complication of pregnancy |
| Q28288350 | Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention |
| Q34181036 | Prevalence and clinical features of patients with the cardiorenal syndrome admitted to an internal medicine ward |
| Q37884733 | Prospective study of epidemiology and prognostic factors in community-acquired pneumonia |
| Q36934379 | Pulmonary and cardiac infections in athletes |
| Q37883934 | Rabbit model for Chlamydia pneumoniae infection |
| Q34108752 | Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen |
| Q44515975 | Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for o |
| Q78816956 | Rapid reduction of Legionella pneumophila on stainless steel with zeolite coatings containing silver and zinc ions |
| Q35649625 | Reasons for choice of antibiotic for the empirical treatment of CAP by Canadian infectious disease physicians |
| Q35763405 | Respiratory Infections in the U.S. Military: Recent Experience and Control |
| Q37885893 | Respiratory infections: community-acquired pneumonia and newer microbes |
| Q33961877 | Respiratory syncytial virus infection in adults |
| Q37481336 | Respiratory syncytial virus vaccine: Is it coming? |
| Q37445302 | Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia |
| Q41451327 | Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections |
| Q36660469 | Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia |
| Q33359963 | SARS: clinical features and diagnosis |
| Q33898654 | Severe community-acquired Enterobacter pneumonia: a plea for greater awareness of the concept of health-care-associated pneumonia. |
| Q87052081 | Severe community-acquired pneumonia |
| Q30471354 | Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study |
| Q44127212 | Sporadic community-acquired Legionnaires' disease in France: a 2-year national matched case-control study |
| Q40662713 | Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society |
| Q40480527 | The Laboratory Diagnosis of Pneumonia: The Role of the Community Hospital Pathologist |
| Q40526847 | The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias |
| Q34521089 | The atypical pneumonias: clinical diagnosis and importance |
| Q51555870 | The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia. |
| Q37098592 | The macrophage scavenger receptor SR-AI/II and lung defense against pneumococci and particles |
| Q37880009 | The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection |
| Q40526860 | Treatment of infections in elderly patients. |
| Q44993851 | Update to the Latin American Thoracic Society (ALAT) Recommendations on Community-Acquired Pneumonia |
| Q51676380 | Usefulness of Gram Stain for Diagnosis of Lower Respiratory Tract Infection or Urinary Tract Infection and as an Aid in Guiding Treatment |
| Q83989479 | Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia |
| Q43965327 | Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia |
| Q34744205 | What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia? |
| Q77053110 | [Community acquired pneumonia in patients older than 60 years. Incidence of atypical agents and clinical-radiological progression] |
| Q73579997 | [Community-acquired pneumonia (CAP) with hospital treatment. The value of the clinical picture and complementary exams in predicting its etiology] |
| Q74521638 | [Community-acquired pneumonia referred for hospital management. Its epidemiology and the diagnostic and therapeutic approaches] |
| Q80617809 | [Infectious pneumonia in the elderly] |
| Q79340135 | [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features] |
Search more.